Pharma C Investments - Board Changes

30 December 2021 

Pharma C Investments Plc

("Pharma C" or the "Company")

Board Changes

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on ancillary businesses, announces that Chana Greenberg has ceased to be a director of the Company with immediate effect.  The Board would like to thank Chana for leading the Company through the IPO process and its initial phase as a quoted company.

Toby Shillito, currently Chief Business Development Officer, will take over Chana's responsibilities as acting CEO and the Board intend to appoint an additional non-executive director in the early part of 2022.

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
 

The Directors of Pharma C Investments plc take responsibility for this announcement.

- Ends -

About Pharma C Investments

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.